MiNK Therapeutics: Buy Rating Backed by Non-Dilutive PRAME iNKT Partnership and Expanded Oncology Upside

TIPRANKS03-10

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on MiNK Therapeutics, with a price target of $35.00. Emily Bodnar has given his Buy...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment